Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

Podobne zapisy

• Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
  od: Heijmans, Stéphane, i wsp.
  Wydane: (2011)
• A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
  od: Nagai, Hideaki, i wsp.
  Wydane: (2010)
• An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
  od: Gillard, Paul, i wsp.
  Wydane: (2012)
• Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials
  od: Roman, François, i wsp.
  Wydane: (2011)
• Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
  od: Garcia-Sicilia, José, i wsp.
  Wydane: (2015)